GlassScriptPhysician profile
Jeremy L Hogan
NPI 1508876905
$109,475.34
in general payments reported to CMS, 2019-2025
40 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $18K · 2021: $17K · 2022: $20K · 2023: $9,997 · 2024: $16K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $2,158 · Travel and Lodging: $1,805 · Consulting Fee: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,450.00 |
| Food and Beverage | $2,158.28 |
| Travel and Lodging | $1,804.61 |
| Consulting Fee | $1,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61,054.49 | 2021-2025 | |
| Allergan, INC. | $40,070.53 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,245.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $2,016.03 | 2021 | |
| Amgen INC. | $325.50 | 2019-2021 | |
| Eisai INC. | $308.99 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $294.62 | 2019-2024 | |
| Biogen, INC. | $250.56 | 2019-2025 | Vumerity |
| Lilly USA, LLC | $217.95 | 2019-2024 | Kisunla |
| Axogen | $192.79 | 2024 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Nerve Protector |
| Genentech USA, INC. | $187.44 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Merz North America, INC. | $159.11 | 2019-2020 | |
| Medtronic, INC. | $134.37 | 2023 | Percept PC Brainsense |
| Merz Pharmaceuticals, LLC | $93.40 | 2021-2024 | Xeomin |
| Livanova USA, INC. | $89.61 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $82.05 | 2020-2024 | Vyepti, Rexulti |
| Pfizer INC. | $76.09 | 2023-2024 | |
| Sk Life Science, INC. | $60.56 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $55.24 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $54.17 | 2019-2021 | |
| Assertio Therapeutics, INC. | $44.14 | 2019 | |
| Janssen Scientific Affairs, LLC | $41.97 | 2024-2025 | |
| Genzyme Corporation | $40.53 | 2019-2020 | |
| Neurelis, INC. | $40.25 | 2022 | |
| Dynasplint Systems INC. | $37.17 | 2021 | |
| Zyla Life Sciences, INC. | $32.25 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $30.23 | 2019 | |
| Emd Serono, INC. | $30.13 | 2019 | |
| Acorda Therapeutics, INC | $28.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.02 | 2019 | |
| Celgene Corporation | $21.12 | 2020 | |
| Ucb, INC. | $16.90 | 2019 | |
| Edw Pharma, INC. | $16.53 | 2020 | |
| Impel Pharmaceuticals INC. | $16.05 | 2022 | |
| Abbott Laboratories | $15.49 | 2019 | |
| Genentech, INC. | $15.43 | 2024 | Ocrevus |
| Medtronic USA, INC. | $14.36 | 2020 | |
| Kyowa Kirin, INC. | $13.42 | 2019 | |
| Insightec,INC | $13.00 | 2019 | |
| Ge Healthcare | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.